Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Serina Therapeutics (SER) over the last 5 years, with Q3 2025 value amounting to $10.3 million.

  • Serina Therapeutics' Shares Outstanding (Diluted Average) fell 383.22% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 383.22%. This contributed to the annual value of $7.4 million for FY2024, which is 10.88% up from last year.
  • Serina Therapeutics' Shares Outstanding (Diluted Average) amounted to $10.3 million in Q3 2025, which was down 383.22% from $10.0 million recorded in Q2 2025.
  • Over the past 5 years, Serina Therapeutics' Shares Outstanding (Diluted Average) peaked at $37.9 million during Q1 2022, and registered a low of $1079.0 during Q4 2022.
  • In the last 5 years, Serina Therapeutics' Shares Outstanding (Diluted Average) had a median value of $8.1 million in 2023 and averaged $10.0 million.
  • Examining YoY changes over the last 5 years, Serina Therapeutics' Shares Outstanding (Diluted Average) showed a top increase of 68117896.2% in 2023 and a maximum decrease of 8040.75% in 2023.
  • Over the past 5 years, Serina Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $37.7 million in 2021, then plummeted by 100.0% to $1079.0 in 2022, then soared by 681178.96% to $7.4 million in 2023, then rose by 0.11% to $7.4 million in 2024, then soared by 40.49% to $10.3 million in 2025.
  • Its last three reported values are $10.3 million in Q3 2025, $10.0 million for Q2 2025, and $9.8 million during Q1 2025.